ALXO
ALX Oncology Holdings Inc.
Biotechnology
Market Cap$112M
5Y Perf.-93.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ALXO vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.62B
5Y Perf.+32.1%
ALXO vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ALXO | RCUS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $112M | $2.62B |
| Revenue (TTM) | $0.00 | $236M |
| Net Income (TTM) | $-108M | $-369M |
| Gross Margin | — | 90.7% |
| Operating Margin | — | -168.6% |
| Total Debt | $17M | $99M |
| Cash & Equiv. | $18M | $222M |
ALXO vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ALXO
RCUS
| Stock | Jul 20 | May 26 | Return |
|---|---|---|---|
| ALX Oncology Holdin… (ALXO) | 100 | 6.4 | -93.6% |
| Arcus Biosciences, … (RCUS) | 100 | 132.1 | +32.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALXO vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALXO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Arcus Biosciences, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ALXO
ALX Oncology Holdings Inc.
The Income Pick
ALXO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.44
- EPS growth 31.0%
- Lower volatility, beta 1.44, Low D/E 14.9%, current ratio 7.26x
Best for: income & stability and growth exposure
RCUS
Arcus Biosciences, Inc.
The Long-Run Compounder
RCUS is the clearest fit if your priority is long-term compounding.
- 52.9% 10Y total return vs ALXO's -93.0%
- -35.3% ROA vs ALXO's -130.6%, ROIC -64.1% vs -71.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALXO | 28.6% revenue growth vs RCUS's -4.3% |
| Quality / Margins | ALXO | 5.2% margin vs RCUS's -156.4% |
| Stability / Safety | ALXO | Beta 1.44 vs RCUS's 1.95, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ALXO | +314.9% vs RCUS's +220.2% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs ALXO's -130.6%, ROIC -64.1% vs -71.8% |
ALXO vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ALXO vs RCUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRCUSLAGGINGALXO
ALXOALX Oncology Holdings…
1leads
RCUSArcus Biosciences, In…
2leads
6 Total Categories
CATEGORYLEADERvs ALXOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALXO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RCUS6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
RCUS4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALXO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RCUS and ALXO operate at a comparable scale, with $236M and $0 in trailing revenue.
| Metric | ALXOALX Oncology Hold… | RCUSArcus Biosciences… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $236M |
| EBITDAEarnings before interest/tax | -$111M | -$391M |
| Net IncomeAfter-tax profit | -$108M | -$369M |
| Free Cash FlowCash after capex | -$97M | -$489M |
| Gross MarginGross profit ÷ Revenue | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | -168.6% |
| Net MarginNet income ÷ Revenue | — | -156.4% |
| FCF MarginFCF ÷ Revenue | — | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +29.3% | +10.5% |
ALXO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ALXO and RCUS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ALXOALX Oncology Hold… | RCUSArcus Biosciences… |
|---|---|---|
| Market CapShares × price | $112M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $111M | $2.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.81x | -7.90x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 10.60x |
| Price / BookPrice ÷ Book value/share | 0.96x | 4.43x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ALXO and RCUS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RCUS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
RCUS delivers a -69.0% return on equity — every $100 of shareholder capital generates $-69 in annual profit, vs $-2 for ALXO. ALXO carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), ALXO scores 2/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | ALXOALX Oncology Hold… | RCUSArcus Biosciences… |
|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -69.0% |
| ROA (TTM)Return on assets | -130.6% | -35.3% |
| ROICReturn on invested capital | -71.8% | -64.1% |
| ROCEReturn on capital employed | -84.8% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 0 |
| Debt / EquityFinancial leverage | 0.15x | 0.16x |
| Net DebtTotal debt minus cash | -$589,000 | -$123M |
| Cash & Equiv.Liquid assets | $18M | $222M |
| Total DebtShort + long-term debt | $17M | $99M |
| Interest CoverageEBIT ÷ Interest expense | -64.62x | -13.38x |
RCUS leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RCUS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $8,629 today (with dividends reinvested), compared to $333 for ALXO. Over the past 12 months, ALXO leads with a +314.9% total return vs RCUS's +220.2%. The 3-year compound annual growth rate (CAGR) favors RCUS at 9.4% vs ALXO's -30.1% — a key indicator of consistent wealth creation.
| Metric | ALXOALX Oncology Hold… | RCUSArcus Biosciences… |
|---|---|---|
| YTD ReturnYear-to-date | +81.7% | +11.6% |
| 1-Year ReturnPast 12 months | +314.9% | +220.2% |
| 3-Year ReturnCumulative with dividends | -65.9% | +31.0% |
| 5-Year ReturnCumulative with dividends | -96.7% | -13.7% |
| 10-Year ReturnCumulative with dividends | -93.0% | +52.9% |
| CAGR (3Y)Annualised 3-year return | -30.1% | +9.4% |
RCUS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALXO and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALXO is the less volatile stock with a 1.44 beta — it tends to amplify market swings less than RCUS's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 90.5% from its 52-week high vs ALXO's 78.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ALXOALX Oncology Hold… | RCUSArcus Biosciences… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 1.95x |
| 52-Week HighHighest price in past year | $2.66 | $28.72 |
| 52-Week LowLowest price in past year | $0.40 | $7.06 |
| % of 52W HighCurrent price vs 52-week peak | +78.6% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 57.7 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 930K | 1.2M |
Evenly matched — ALXO and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ALXO as "Buy" and RCUS as "Buy". Consensus price targets imply 91.4% upside for ALXO (target: $4) vs 15.4% for RCUS (target: $30).
| Metric | ALXOALX Oncology Hold… | RCUSArcus Biosciences… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $30.00 |
| # AnalystsCovering analysts | 7 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCUS leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALXO leads in 1 (Income & Cash Flow). 2 tied.
Best OverallArcus Biosciences, Inc. (RCUS)Leads 2 of 6 categories
Loading custom metrics...
ALXO vs RCUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ALXO or RCUS a better buy right now?
Analysts rate ALX Oncology Holdings Inc.
(ALXO) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALXO or RCUS?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -13. 7%, compared to -96. 7% for ALX Oncology Holdings Inc. (ALXO). Over 10 years, the gap is even starker: RCUS returned +52. 9% versus ALXO's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALXO or RCUS?
By beta (market sensitivity over 5 years), ALX Oncology Holdings Inc.
(ALXO) is the lower-risk stock at 1. 44β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 36% more volatile than ALXO relative to the S&P 500. On balance sheet safety, ALX Oncology Holdings Inc. (ALXO) carries a lower debt/equity ratio of 15% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ALXO or RCUS?
On earnings-per-share growth, the picture is similar: ALX Oncology Holdings Inc.
grew EPS 31. 0% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALXO or RCUS?
ALX Oncology Holdings Inc.
(ALXO) is the more profitable company, earning 0. 0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALXO leads at 0. 0% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ALXO or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ALXO or RCUS better for a retirement portfolio?
For long-horizon retirement investors, ALX Oncology Holdings Inc.
(ALXO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALXO: -93. 0%, RCUS: +52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ALXO and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.